Orum Therapeutics
Peter U. Park has a diverse work experience spanning several companies in the biotechnology and pharmaceutical industries. Starting in 2006, they worked at ImmunoGen, Inc. as a Senior Director in Discovery Research until 2012. In 2012, they co-founded Habgen, Inc. and served as the CEO until the end of the year. From 2013 to 2015, they held the position of Vice President of Biology at Mersana Therapeutics. In 2015, they founded Iokine Pharmaceuticals and remained there until 2016. Following that, they joined Bicycle Therapeutics as the Vice President of Oncology Research from 2016 to 2018. Peter U. then joined Orum Therapeutics in 2019, initially as a Chief Scientific Officer until 2023 and also served as a member of the Board of Directors. Currently, they are the Chief Executive Officer at Tesseract Medicines starting from May 2023.
Peter U. Park has a Bachelor of Science (B.S.) degree in Biology from the Massachusetts Institute of Technology. Peter U. also holds a Ph.D. degree in Biology from the same institution. However, the specific start and end years for both degrees are unavailable.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.